Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Katrine L. H. Weischenfeldt, Tove Kirkegaard, Birgitte B. Rasmussen, Anita Giobbie-Hurder, Maj-Britt Jensen, Bent Ejlertsen & Anne E. Lykkesfeldt. (2017) A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis. Acta Oncologica 56:9, pages 1161-1167.
Read now
Read now
Articles from other publishers (22)
Daryush Purrahman, Mohammad-Reza Mahmoudian-Sani, Najmaldin Saki, Piotr Wojdasiewicz, Iwona Kurkowska-Jastrzębska & Łukasz A. Poniatowski. (2022) Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer. Cytokine 151, pages 155803.
Crossref
Crossref
Ines Barone, Amanda Caruso, Luca Gelsomino, Cinzia Giordano, Daniela Bonofiglio, Stefania Catalano & Sebastiano Andò. (2021) Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives. Obesity Reviews 23:2.
Crossref
Crossref
Asona Lui, Jacob New, Joshua Ogony, Sufi Thomas & Joan Lewis-Wambi. (2016) Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells. BMC Cancer 16:1.
Crossref
Crossref
S Thrane, A M Pedersen, M B H Thomsen, T Kirkegaard, B B Rasmussen, A K Duun-Henriksen, A V Lænkholm, M Bak, A E Lykkesfeldt & C W Yde. (2014) A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Oncogene 34:32, pages 4199-4210.
Crossref
Crossref
D Elias, H Vever, A-V Lænkholm, M F Gjerstorff, C W Yde, A E Lykkesfeldt & H J Ditzel. (2014) Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene 34:15, pages 1919-1927.
Crossref
Crossref
Sarah L. Larsen, Anne-Vibeke Laenkholm, Anne Katrine Duun-Henriksen, Martin Bak, Anne E. Lykkesfeldt & Tove Kirkegaard. (2015) Src Drives Growth of Antiestrogen Resistant Breast Cancer Cell Lines and Is a Marker for Reduced Benefit of Tamoxifen Treatment. PLOS ONE 10:2, pages e0118346.
Crossref
Crossref
Sarah A. Dabydeen, Keunsoo Kang, Edgar S. Díaz-Cruz, Ahmad Alamri, Margaret L. Axelrod, Kerrie B. Bouker, Rawan Al-Kharboosh, Robert Clarke, Lothar Hennighausen & Priscilla A. Furth. (2015) Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance. Carcinogenesis 36:1, pages 122-132.
Crossref
Crossref
Kristina E Aaltonen, Ann H Rosendahl, Hans Olsson, Per Malmström, Linda Hartman & Mårten Fernö. (2014) Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer. BMC Cancer 14:1.
Crossref
Crossref
Charlotte Levin Tykjær Jørgensen, Christina Bjerre, Bent Ejlertsen, Karsten D Bjerre, Eva Balslev, Annette Bartels, Nils Brünner & Dorte L Nielsen. (2014) TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group. BMC Cancer 14:1.
Crossref
Crossref
Anieta M. Sieuwerts, Maria B. Lyng, Marion E. Meijer-van Gelder, Vanja de Weerd, Fred C.G.J. Sweep, John A. Foekens, Paul N. Span, John W.M. Martens & Henrik J. Ditzel. (2014) Evaluation of the ability of adjuvant tamoxifen‐benefit gene signatures to predict outcome of hormone‐naive estrogen receptor‐positive breast cancer patients treated with tamoxifen in the advanced setting. Molecular Oncology 8:8, pages 1679-1689.
Crossref
Crossref
Karin Beelen, Mark Opdam, Tesa M Severson, Rutger HT Koornstra, Andrew D Vincent, Jelle Wesseling, Jettie J Muris, Els MJJ Berns, Jan B Vermorken, Paul J van Diest & Sabine C Linn. (2014) PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Research 16:1.
Crossref
Crossref
Arthur Adams, Aram SA van Brussel, Jeroen F Vermeulen, Willem PThM Mali, Elsken van der Wall, Paul J van Diest & Sjoerd G Elias. (2013) The potential of hypoxia markers as target for breast molecular imaging – a systematic review and meta-analysis of human marker expression. BMC Cancer 13:1.
Crossref
Crossref
Guihua Zhai, Clinton J. Grubbs, Cecil R. Stockard, Heidi R. Umphrey, T. Mark Beasley & Hyunki Kim. (2013) Diffusion Weighted Imaging Evaluated the Early Therapy Effect of Tamoxifen in an MNU-Induced Mammary Cancer Rat Model. PLoS ONE 8:5, pages e64445.
Crossref
Crossref
S Cutrupi, S Reineri, A Panetto, E Grosso, L Caizzi, L Ricci, O Friard, S Agati, M Scatolini, G Chiorino, A E Lykkesfeldt & M De Bortoli. (2012) Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells. Oncogene 31:40, pages 4353-4361.
Crossref
Crossref
Karin Beelen, Wilbert Zwart & Sabine C. Linn. (2012) Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nature Reviews Clinical Oncology 9:9, pages 529-541.
Crossref
Crossref
Anne-Vibeke Laenkholm, Ann Knoop, Bent Ejlertsen, Tine Rudbeck, Maj-Britt Jensen, Sven Müller, Anne Elisabeth Lykkesfeldt, Birgitte Bruun Rasmussen & Kirsten Vang Nielsen. (2012)
ESR1
gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry
. Molecular Oncology 6:4, pages 428-436.
Crossref
Crossref
Jeffrey D Altenburg, Andrew A Bieberich, Colin Terry, Kevin A Harvey, Justin F VanHorn, Zhidong Xu, V Jo Davisson & Rafat A Siddiqui. (2011) A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone. BMC Cancer 11:1.
Crossref
Crossref
H. Anderson, M. Hills, L. Zabaglo, R. A'Hern, A.F. Leary, B.P. Haynes, I.E. Smith & M. Dowsett. (2011) Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer. Annals of Oncology 22:8, pages 1770-1776.
Crossref
Crossref
A. C. Regierer, R. Wolters, C. Kurzeder, A. Wöckel, I. Novopashenny, K. Possinger, M. B. Wischnewsky & R. Kreienberg. (2011) High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?. Breast Cancer Research and Treatment 128:1, pages 273-281.
Crossref
Crossref
Diana M. Cittelly, Partha M. Das, Virgilio A. Salvo, Juan P. Fonseca, Matthew E. Burow & Frank E. Jones. (2010) Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 31:12, pages 2049-2057.
Crossref
Crossref
Angela M. Betancourt, Isam A. Eltoum, Renee A. Desmond, Jose Russo & Coral A. Lamartiniere. (2010)
In Utero
Exposure to Bisphenol A Shifts the Window of Susceptibility for Mammary Carcinogenesis in the Rat
. Environmental Health Perspectives 118:11, pages 1614-1619.
Crossref
Crossref
Anne E Lykkesfeldt, Katrine L Henriksen, Birgitte B Rasmussen, Hironobu Sasano, Dean B Evans, Susanne Møller, Bent Ejlertsen & Henning T Mouridsen. (2009) In situaromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer. BMC Cancer 9:1.
Crossref
Crossref